Estimation of direct costs of melanoma in the Veneto Region

a budget assessment and cost-consequence analysis

Alessandra Buja, Gino Sartor, Manuela Scioni, Giovanni Girardi, Antonella Vecchiato, Mario Bolzan, Vincenzo Rebba, Vanna Chiarion Sileni, Angelo C Palozzo, Maria Montesco, Paolo Del Fiore, Vincenzo Baldo, Carlo R Rossi

Research output: Contribution to journalArticle

Abstract

BACKGROUND: While many evidence-based pathways have been introduced to drive quality improvements in cancer care, most of these do not include evidence about their affordability. The main aim of this study is to provide an estimation of the overall budget to cover all the needs of melanoma patients in Veneto Region, managed according to the clinical pathway defined by the Rete Oncologica Veneta. A second objective is to conduct a cost-consequence analysis, comparing two different treatments.

METHODS: A very detailed whole-disease model was developed describing the patient's pathway from diagnosis through the first year of follow-up. Each procedure involved in the model was associated with a likelihood measure and a cost. The model can be used to estimate the expected direct costs associated with melanoma.

RESULTS: We can observe that 0 and I stage, despite accounting for a huge percentage of new melanoma cases are characterized by a small percentage of the total costs. Stage III can be considered as the most expensive stage accounting for 54% of the total costs with a 12% of patients. Finally, the stage IV patients, although very few account for almost the 7% of the total costs. Regarding the cost-consequence analysis, it was estimated that the therapies introduced in 2016 led to an approximately 14% increase in the total costs.

CONCLUSIONS: Modeling a clinical pathway with a high level of detail enables to identify the main sources of spending. The consequent analysis can thus help policy-makers to plan the future resources allocation.

Original languageEnglish
Pages (from-to)1-7
Number of pages7
JournalGiornale Italiano di Dermatologia e Venereologia
DOIs
Publication statusE-pub ahead of print - Nov 9 2018

Fingerprint

Budgets
Melanoma
Costs and Cost Analysis
Critical Pathways
Resource Allocation
Quality Improvement
Administrative Personnel
Therapeutics

Cite this

Estimation of direct costs of melanoma in the Veneto Region : a budget assessment and cost-consequence analysis. / Buja, Alessandra; Sartor, Gino; Scioni, Manuela; Girardi, Giovanni; Vecchiato, Antonella; Bolzan, Mario; Rebba, Vincenzo; Chiarion Sileni, Vanna; Palozzo, Angelo C; Montesco, Maria; Del Fiore, Paolo; Baldo, Vincenzo; Rossi, Carlo R.

In: Giornale Italiano di Dermatologia e Venereologia, 09.11.2018, p. 1-7.

Research output: Contribution to journalArticle

@article{c718b4302f2d48b2be72e5458894a8eb,
title = "Estimation of direct costs of melanoma in the Veneto Region: a budget assessment and cost-consequence analysis",
abstract = "BACKGROUND: While many evidence-based pathways have been introduced to drive quality improvements in cancer care, most of these do not include evidence about their affordability. The main aim of this study is to provide an estimation of the overall budget to cover all the needs of melanoma patients in Veneto Region, managed according to the clinical pathway defined by the Rete Oncologica Veneta. A second objective is to conduct a cost-consequence analysis, comparing two different treatments.METHODS: A very detailed whole-disease model was developed describing the patient's pathway from diagnosis through the first year of follow-up. Each procedure involved in the model was associated with a likelihood measure and a cost. The model can be used to estimate the expected direct costs associated with melanoma.RESULTS: We can observe that 0 and I stage, despite accounting for a huge percentage of new melanoma cases are characterized by a small percentage of the total costs. Stage III can be considered as the most expensive stage accounting for 54{\%} of the total costs with a 12{\%} of patients. Finally, the stage IV patients, although very few account for almost the 7{\%} of the total costs. Regarding the cost-consequence analysis, it was estimated that the therapies introduced in 2016 led to an approximately 14{\%} increase in the total costs.CONCLUSIONS: Modeling a clinical pathway with a high level of detail enables to identify the main sources of spending. The consequent analysis can thus help policy-makers to plan the future resources allocation.",
author = "Alessandra Buja and Gino Sartor and Manuela Scioni and Giovanni Girardi and Antonella Vecchiato and Mario Bolzan and Vincenzo Rebba and {Chiarion Sileni}, Vanna and Palozzo, {Angelo C} and Maria Montesco and {Del Fiore}, Paolo and Vincenzo Baldo and Rossi, {Carlo R}",
year = "2018",
month = "11",
day = "9",
doi = "10.23736/S0392-0488.18.06106-0",
language = "English",
pages = "1--7",
journal = "Giornale Italiano di Dermatologia e Venereologia",
issn = "0392-0488",
publisher = "Edizioni Minerva Medica S.p.A.",

}

TY - JOUR

T1 - Estimation of direct costs of melanoma in the Veneto Region

T2 - a budget assessment and cost-consequence analysis

AU - Buja, Alessandra

AU - Sartor, Gino

AU - Scioni, Manuela

AU - Girardi, Giovanni

AU - Vecchiato, Antonella

AU - Bolzan, Mario

AU - Rebba, Vincenzo

AU - Chiarion Sileni, Vanna

AU - Palozzo, Angelo C

AU - Montesco, Maria

AU - Del Fiore, Paolo

AU - Baldo, Vincenzo

AU - Rossi, Carlo R

PY - 2018/11/9

Y1 - 2018/11/9

N2 - BACKGROUND: While many evidence-based pathways have been introduced to drive quality improvements in cancer care, most of these do not include evidence about their affordability. The main aim of this study is to provide an estimation of the overall budget to cover all the needs of melanoma patients in Veneto Region, managed according to the clinical pathway defined by the Rete Oncologica Veneta. A second objective is to conduct a cost-consequence analysis, comparing two different treatments.METHODS: A very detailed whole-disease model was developed describing the patient's pathway from diagnosis through the first year of follow-up. Each procedure involved in the model was associated with a likelihood measure and a cost. The model can be used to estimate the expected direct costs associated with melanoma.RESULTS: We can observe that 0 and I stage, despite accounting for a huge percentage of new melanoma cases are characterized by a small percentage of the total costs. Stage III can be considered as the most expensive stage accounting for 54% of the total costs with a 12% of patients. Finally, the stage IV patients, although very few account for almost the 7% of the total costs. Regarding the cost-consequence analysis, it was estimated that the therapies introduced in 2016 led to an approximately 14% increase in the total costs.CONCLUSIONS: Modeling a clinical pathway with a high level of detail enables to identify the main sources of spending. The consequent analysis can thus help policy-makers to plan the future resources allocation.

AB - BACKGROUND: While many evidence-based pathways have been introduced to drive quality improvements in cancer care, most of these do not include evidence about their affordability. The main aim of this study is to provide an estimation of the overall budget to cover all the needs of melanoma patients in Veneto Region, managed according to the clinical pathway defined by the Rete Oncologica Veneta. A second objective is to conduct a cost-consequence analysis, comparing two different treatments.METHODS: A very detailed whole-disease model was developed describing the patient's pathway from diagnosis through the first year of follow-up. Each procedure involved in the model was associated with a likelihood measure and a cost. The model can be used to estimate the expected direct costs associated with melanoma.RESULTS: We can observe that 0 and I stage, despite accounting for a huge percentage of new melanoma cases are characterized by a small percentage of the total costs. Stage III can be considered as the most expensive stage accounting for 54% of the total costs with a 12% of patients. Finally, the stage IV patients, although very few account for almost the 7% of the total costs. Regarding the cost-consequence analysis, it was estimated that the therapies introduced in 2016 led to an approximately 14% increase in the total costs.CONCLUSIONS: Modeling a clinical pathway with a high level of detail enables to identify the main sources of spending. The consequent analysis can thus help policy-makers to plan the future resources allocation.

U2 - 10.23736/S0392-0488.18.06106-0

DO - 10.23736/S0392-0488.18.06106-0

M3 - Article

SP - 1

EP - 7

JO - Giornale Italiano di Dermatologia e Venereologia

JF - Giornale Italiano di Dermatologia e Venereologia

SN - 0392-0488

ER -